A handful of biotech companies are pursuing the development of microbiome drugs, and many prominent investors are placing their bets. With $35 million series B funding led by Sequoia Capital, Whole Biome is on track to start selling a capsule for type 2 diabetes early next year. Whole Biome’s capsule helps patients restore gut bacteria, that […]

Know more, do more.

You'll get access to all of our original analysis, exclusive features, and more for just $9.